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(57) ABSTRACT
This invention provides a novel method for purifying syn­
thetic oligomers comprising capping, polymerizing and sepa­
rating any failure sequences produced during oligomer syn­
thesis. Either the failure sequence or the full-length oligomer 
may be polymerized. Optionally, small molecule impurities 
may also be incorporated into the polymerized material. The 
invention provides novel capping agents having a polymeriz­
able functional group. The invention also provides kits com­
prising at least one composition of the present invention.
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PURIFICATION OF SYNTHETIC 
OLIGOMERS
CROSS-REFERENCE TO RELATED 
APPLICATIONS
This application claims priority under 35 U.S.C. §119(e)to 
U.S. Provisional Patent Application No. 60/827,592 filed 
Sep. 29, 2006, which is hereby incorporated by reference.
INTRODUCTION
Synthetic oligonucleotides have wide applications in biol­
ogy and medicine. With one oligonucleotide drug on the 
market and more than 40 others in various stages of clinical 
trials, the interest in using oligonucleotides as therapeutic 
agents continues to grow. This growing demand requires 
large quantities of oligonucleotides. For many purposes, 
including use as therapeutic agents to cure human diseases, 
these crude oligonucleotides must be purified to remove the 
failure sequences generated in the coupling steps in the syn­
thesis. Currently used purification methods include gel elec­
trophoresis, HPLC and others—all of which are expensive, 
labor intensive and unsuitable for large scale purification. The 
most frequently used purification methods such as gel elec­
trophoresis are not suitable for large scale purification. 
Reverse phase and ion exchange HPLC have been adapted to 
large scale purification, but there are high costs associated 
with instrumentation, eluents (including their evaporation) 
and columns. Other known purification methods are also not 
ideal. Consequently, the development of highly efficient and 
low cost methods for large scale production of oligonucle­
otides is desired.
SUMMARY OF THE INVENTION
The present invention provides a method of purifying oli­
gomers comprising capping any failure sequences produced 
during synthesis with a capping agent having a polymerizable 
functional group, polymerizing the capped failure sequences; 
and separating the polymerized material from the full-length 
oligomer.
The present invention also provides a method of purifying 
an oligomer comprising attaching a polymerizable functional 
group to an end of a full length oligomer, polymerizing the 
full length oligomers, removing the failure sequences from 
the polymerized full length oligomers, and recovering the full 
length oligomers.
In addition, the present invention provides capping agents 
comprising polymerizable functional groups and its for puri­
fying oligomers.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates one method for oligonucleotide purifica­
tion. Unwanted failure sequences contain polymerizable 
function, while the desired full length sequences do not. After 
polymerization, failure sequences are incorporated into a 
polymer, and full length sequences are isolated by simple 
extraction.
FIG. 2 illustrates an additional method for oligonucleotide 
purification. Desired full length sequences contain polymer­
izable function, while unwanted sequences do not. After 
polymerization, full length sequences are incorporated into a 
polymer, failure sequences are removed by washing, and full 
length sequences are cleaved from the polymer and extracted 
with a buffer.
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FIG. 3 represents the chemical reaction for formation of 
polyacrylamide gel.
FIG. 4 represents the chemical reaction for synthesis of the 
capping agents 22-24.
FIG. 5 illustrated the structures of full length sequence and 
failure sequences when using 22-24 as capping agents.
FIG. 6 represents the chemical reaction for formation of 
disulfide polymer.
FIG. 7 represents the chemical reaction for synthesis of 
capping agents 39 and 40.
FIG. 8 represents the chemical reaction for synthesis of 
copolymerization agents 44 and 45.
FIG. 9 represents the chemical reaction for synthesis of 
capping agents 50 and 51.
FIG. 10 represents the chemical reaction for synthesis of 
copolymerization agents 55 and 56.
FIG. 11 represents the Sharpless “click” reaction.
FIG. 12 represents the chemical reaction for synthesis of 
capping agents 57-60.
FIG. 13 represents the chemical reaction for synthesis of 
copolymerization agents 65 and 66.
FIG. 14 represents the water soluble Grubbs’ ROMP cata­
lysts.
FIG. 15 represents the Grubbs’ ROMP reaction.
FIG. 16 represents the chemical reaction for synthesis of 
capping agents 74-77, and the copolymerization agents 78 
and 79.
FIG. 17 represents the conjugate addition reaction between 
maleimide and thiol.
FIG. 18 represents the chemical reaction for synthesis of 
capping agents 82 and 83, and the copolymerization agents 55 
and 56, and 84, 85 and 86.
FIG. 19 represents the chemical reaction for synthesis of 
phosphoramidites 92 and 95.
FIG. 20 represents the full length oligonucleotides after 
deprotection and cleavage using phosphoramidites 92 and95.
FIG. 21 represents the chemical reaction of cleavage of 
DNAs 98 and 100 from polymer.
FIG. 22 represents the chemical reaction for synthesis of 
phosphoramidites 103 and 105.
FIG. 23 represents the structures of the oligonucleotides 
after deprotection and cleavage, using 103 or 105 as the 
phosphoramidite in the last synthetic cycle in oligonucleotide 
synthesis.
FIG. 24 represents the chemical reaction for the cleavage of 
DNAs 98 and 100 from polymer.
FIG. 25 represents the chemical reaction for synthesis of 
phosphoramidites 113 and 115.
FIG. 26 are the structures of the oligonucleotides after 
deprotection and cleavage, using 113 or 115 as phosphora­
midite in the last synthetic cycle in oligonucleotide synthesis.
FIG. 27 represents the chemical reaction for cleavage of 
DNAs 98 and 100 from polymer.
FIG. 28 represents the chemical reaction for synthesis of 
phosphoramidites 122 and 124.
FIG. 29 represents the structures of the oligonucleotides 
after deprotection and cleavage, using 122 or 124 as phos­
phoramidite in the last synthetic cycle in oligonucleotide 
synthesis.
FIG. 30 represents the chemical reaction for cleavage of 
DNAs 98 and 100 from polymer.
FIG. 31 represents the chemical reaction for synthesis of 
phosphoramidites 132 and 134.
FIG. 32 represents the chemical structures for the oligo­
nucleotides after deprotection and cleavage, using 132 or 134 
as phosphoramidite in the last synthetic cycle in oligonucle­
otide synthesis.
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FIG. 33 represents the chemical reaction forthe cleavage of 
DNAs 98 and 100 from polymer.
FIG. 34 represents the chemical reaction for the synthesis 
of capping agent 141.
FIG. 35 represents the chemical reaction for the synthesis 
of phosphoramidites 150.
DETAILED DESCRIPTION OF THE INVENTION
The present invention includes a method of purifying syn­
thetic oligomers via a polymerization technique, capping 
agents having a polymerizable functional group, and kits for 
purifying oligomers comprising a capping agent having poly- 
erizable functional group. Synthesis of oligomers generally 
proceeds in a step-wise manner with each monomer being 
added in sequence to the ends of a plurality growing oligomer. 
After synthesis and deprotection/cleavage, crude oligomers 
normally contains the following impurities:
(i) Truncated failure sequences. These impurities result 
from the coupling steps of the synthesis. For a successful 
20-mer synthesis, these impurities comprise about 30% of the 
oligonucleotide content of the crude mixture. They have simi­
lar physical properties as the desired full length sequences, 
and so are difficult to remove. They are usually capped with 
acetic anhydride in the synthesis. As a result, if the 5'-OH 
DMTr (4,4'-dimethoxytrifyl) protecting groups in the last 
synthesis cycle are not removed, then after basic deprotection 
and cleavage, the full length sequences have the hydrophobic 
DMTr group on their 5'-end while the failure sequences do 
not (acyl groups on the failure sequences are removed under 
deprotection conditions). This is the basis of DMTr-on 
reverse phase HPLC purification. Although this is the most 
widely used oligonucleotide purification method, it is very 
costly for large scale production.
(ii) Small organic impurities. These result from the phos­
phate and exo-amino protecting groups which include acry­
lonitrile, benzamide, acetamide and isobutyramide and others 
depending on which protecting groups are used. Because of 
their very different physical properties from oligonucle­
otides, they can be removed by precipitation from aqueous 
buffer with ethanol or 2-propanol.
(iii) Other oligonucleotide impurities. These are very dif­
ficult to remove; fortunately, only very limited quantities are 
typically present. Two examples are N+l and N+2 sequences, 
which result from double coupling due to the mild acidity of 
activating agents that causes premature detritylation in the 
coupling step. They can be troublesome to remove even on 
small scale. When the DMTr-on reverse phase HPLC strategy 
is used, they also contain a 5'-DMTr group. Ion exchange 
HPLC cannot resolve a single nucleotide difference for a 
typical 20-mer. Gel electrophoresis can do the job but can 
only on a very small scale. Additional impurities are acryloni­
trile-oligonucleotide adducts. In addition, for oligophospho- 
rothioate synthesis, because of incomplete sulffirization, 
impurities such as (?= ())!  and (P = 0 )2 mers exist, they can 
be kept to a minimum amount by using a more efficient 
sulffirization agent.
These impurities need to be separated from the desired 
full-length oligomer when synthesis is complete. The present 
invention contemplates the purification of oligomers through 
the use of capping agents containing polymerizable func­
tional groups. Both failure sequences and small organic 
impurities can be removed using the method of the present 
invention.
As used herein, “oligomer” includes oligonucleotides, 
modified oligonucleotides, polynucleotides, modified poly­
nucleotides, oligosaccharides, modified oligosaccharides, 
polysaccharides, modified polysaccarides, peptides, modi­
fied peptides, polypeptides, modified polypeptides, and any 
conjugates of two or more of these different types of oligo­
3
mers such as peptide nucleic acid conjugates and glycopep- 
tides. Modified oligomers include peptide nucleic acids, 
locked DNA, phosphotihioate oligonucleotides, beta-pep- 
tides and quaternary peptides. Modifications to oligosaccha­
rides include alterations of ring size, ring atoms and various 
substitutions on the sugar rings. One of ordinary skill in the art 
can envision other modified oligomers which fall within the 
scope of the present invention. Oligomers may contain both 
natural and unnatural monomers. For example, both D- and 
L-amino acids can be used. The term “oligomer” is not 
intended to be limited to any specific number of monomers. 
Instead, it is meant to encompass an oligomer (or polymer) of 
any length that can be made by a step-wise process.
As used herein, “failure sequence” means an oligomer to 
which the next monomer did not attach during synthesis. 
Thus, a failure sequence of any given step in the synthesis 
contains all monomers except for the most recently added 
monomer.
As used herein, “lower alkyl” means an alkyl group of 1 to 
4 carbon atoms, that may be branched, such as methyl, ethyl, 
propyl, isopropyl and butyl.
The oligomer purification methods of the present invention 
are suitable for both laige and small scale purification. Oli­
gomers purified by the methods of the present invention are 
substantially free of failure sequences and have similar or 
better qualify than those purified by DMTr-on reverse phase 
HPLC method. The purified oligomer may be of greater than 
about 90% purify, or greater than about 95%, or greater than 
about 97%, or greater than about 99% or greater than about 
99.5%. By “substantially free”, it is meant that the oligomer 
contains less than about 5% by weight of failure sequences, or 
less than about 3%, or less than about 1% or less than about 
0.5%.
In one embodiment of the present invention, simple phos­
phorous compounds that contain functional groups capable of 
polymerizing in the presence of an initiator and/or a polymer­
ization partner are used as capping agents (in place of the 
commonly used acetic anhydride) during oligomer synthesis 
to block failure sequences. Thus, all unwanted failure 
sequences contain the polymerizable functions, while the 
desired full length sequences do not. After synthesis, failure 
sequences are incorporated into a polymerized material, and 
the full length oligomers remain in solution or in the polymer 
matrix and are separated from the polymerized material using 
any technique known to one of ordinary skill in the art includ­
ing extraction with buffer and filtration. If the oligomer is 
synthesized on a solid support, the oligomer can be cleaved 
from the solid support prior to polymerization. (See FIG. 1).
In another embodiment of the present invention, polymer­
izable functional groups are incorporated onto the end of the 
full length sequences in the last step of oligomer synthesis. 
Because failure sequences are capped with a standard cap­
ping agent, such as acetic anhydride, dimethyl-formanide, 
diethylene glycol monoethyl ether phosphoramidite, or b is(l, 
l,l,3,3,3-hexafluoro-2-propyl)-2-propyl phosphate, in each 
synthetic cycle, only the full length sequence contains the 
polymerizable functional group. Once the full length 
sequences are incorporated into a polymerized material, the 
failure sequences are removed by simple washing because 
they do not contain a polymerizable functional group, and 
then, full length sequences are recovered from the polymer­
ized material using a cleavage reagent. (See FIG. 2). If the 
synthesis occurs on a solid support, the oligomer can be 
cleaved from the solid support before or after polymerization.
Using either of these methods, the small molecules resulted 
from deprotection of nucleobases and phosphate groups can 
also be removed if suitable polymerizable functions are incor­
porated into the protecting groups. When the first method is 
used, the small molecules resulted from deprotection will be 
incorporated into the polymerized material in the same fash­
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ion as the failure sequences are incorporated. When the sec­
ond method is used, the small molecules resulted from depro­
tection will also be incorporated into the polymerized 
material. However, the full length sequence can be cleaved 
from the polymerized material and the small molecule impu­
rities cannot because there is no cleavable linker in them.
Polymerization reactions suitable for the methods of the 
present invention have one or more of the following charac­
teristics: (i) the polymerization reaction is highly efficient 
once initiated; (ii) the reaction tolerates moisture and air and, 
suitably, can be performed in aqueous buffer; (iii) oligomers 
are stable under the polymerization conditions; and (iv) the 
polymerizable functional groups are easily accessible and are 
stable under oligomer synthesis conditions.
Reactions that are suitable for oligonucleotide purification 
include, but are not limited to, the radical acrylamide poly­
merization reaction, the thiol oxidation to disulfide reaction, 
the Sharpless “click” reaction, the Grubbs aqueous ROMP 
reaction, the conjugate addition reaction between maleimide 
and thiol, and the amide bond formation reaction between 
carboxylic acid esters and alkyl amines. Reactions that are 
suitable for oligosaccharide and peptide purification include, 
but are not limited to, the Sharpless “click” reaction.
Radical Acrylamide Polymerization
The general acrylamide polymerization reaction is shown 
in FIG. 3. The materials for this reaction are inexpensive, and 
the reaction is highly efficient and can be performed in aque­
ous buffer open to air at room temperature. In addition, acry­
lamide functionalities are stable under oligonucleotide syn­
thesis and deprotection/cleavage conditions using 
phosphoramidite chemistry. Appropriate polymerization 
conditions can be readily determined by one of ordinary skill 
in the art. Suitable conditions include (NH4)2S20 8/TMEDA/ 
water at room temperature for about 1 hour. For example, for 
a 1 mmol oligonucleotide synthesis, optionally about 10 
mmol to about 100 mmol acrylamide, optionally about 0.2 
mmol to about 2.0 mmol N,N'-methylene-bisacrylamide, 
about 1 pmol to about 10 tpmol (NH4)2S20 8, and about 1 
pmol to about 10 pmol TMDEA may be used.
Suitable capping agents for purification using radical acry­
lamide polymerization include compounds of formula (I):
5
wherein R2 is halogen, such as Cl, Br, or F or a secondary 
amine group, such as
Rio
----- N
\
Rio;
R2 is independently selected from lower alkyl,
R9 is an electron withdrawing group such as cyano, 
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and 
at least one R2 is
6
Suitably, the capping agent contains more than one polymer­
izable functional group. It is hypothesized that additional 
polymerizable functional groups on the capping agent 
increase the likelihood that capped polymers will be incorpo­
rated into the polymer.
However, capping agents containing only one polymeriz­
able functional group have the advantage of more stable under 
basic deprotection/cleavage conditions when the other R2 is a 
removable group such as 2-cyanoethyl group.
When R2 is a secondary amino group, the capping agents 
for radical acrylamide polymerization require the use of an 
activating agent. The most commonly used activating agent is 
lH-tetrazole. Other suitable activating agents include, but are 
not limited to 4,5-dicyanoimidazole, 5-(4-nitrophenyl)-lH- 
tetrazole, 5-methylthio-lH-tetrazole, 5-ethylthio-lH-tetra- 
zole, ethylthiotetrazole, and 5-benzylmereapto-lH-tetrazole.
Optionally, when R2 is a halogen atom, a base may be 
added to neutralize acid produced during the capping reac­
tion. The base may be an amine base such as trimethylamine, 
pyridine, diazobicyclo base, or 5-methoxybenzimidazole.
Syntheses of suitable phosphorous capping agents 22-24 
(shown below) are shown in FIG. 4.
22
H
Compounds 22 and 23 contain two polymerizable func­
tional groups, which can increase the likelihood that failure 
sequences will be incorporated into the polymer. Compound 
24 contains only one polymerizable functional group. When 
compound 22 is used for capping, an activator is required. If 
23 or 24 is used, no activating agent is required, but an amine 
base, such as trimethylamine, pyridine, diazobicyclo base, or 
5 -methoxybenzimidazole, must be used to neutralize the acid 
generated.
Because there is less concern about premature detritylation 
in capping steps than in coupling steps, other capping agents 
such as ammonium salts developed by Beaucage, Caruthers 
and Wada and co-workers can be used.
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For purification of oligomers using polyacrylamide forma­
tion reaction, an alternative procedure is to use a fluoride 
cleavable linker to attach the growing oligomers to the solid 
support (instead of using the more common base cleavable 
linkers; besides fluoride cleavable linkers, other non-base 
cleavable linker such as photo cleavable linkers can also be 
used) for oligomer synthesis. After synthesis, the oligomers 
are cleaved from the solid support by treating with fluoride. 
The crude un-deprotected oligomers are subjected to poly­
merization reaction conditions. The failure sequences are 
incorporated into a polymerized material and the full length 
sequences remain in solution or in polymer matrix. After 
removal of failure sequences by filtration and extraction of the 
full length sequences from polymer matrix, the full length 
sequences are subjected to base de-protection conditions and 
further purified by recrystallization to remove small mol­
ecules resulted from de-deprotection. This alternative purifi­
cation procedure avoids the possibility of adding nucleo­
philes to acrylamide functionalities in the base de-protection 
steps.
Formation of Disulfide Polymer
Thiols may be oxidized to form polymers. One of ordinary 
skill in the art can determine polymerization conditions that 
are suitable for such polymerization. For example, for a 1 
mmol oligonucleotide synthesis, about 10 mmol to about 100 
mmol of a copolymerization agent and about 0.2 mmol to 
about 2 mmol of a cross-linking copolymerization agent that 
contains more than 2 thiols in one molecule such as 45 and 56 
can be used. Suitably, the mixture is heated in dimethylsul- 
foxide, for example, to about 90° C. If dimethylsulfoxide is 
used as a solvent, no additional oxidizing agent is necessary. 
If another solvent is used, then an oxidizing agent, such as 
oxygen or others known to those skilled in the art should be 
added.
Suitable capping agents for purification using formation of 
a disulfide polymer include compounds of formula (I):
7
r 3o  o r 3
wherein R3 is halogen, such as Cl, Br or F or a secondary 
amine, such as
^Rio
----- N
\
Rio;
R3 is independently selected from lower alkyl or
n is an integer from 1 to 5; 
m is an integer from 0 to 4;
R9 is an electron withdrawing group such as cyano, 
COOR10, S 0 2Ph and N 0 2; and 
R10 is lower alkyl.
Suitable copolymerization agents include compounds of 
formula (III):
8
wherein n is an integer from 1 to 5; 
q is independently an integer from 0 to 3; and 
r is independently an integer from 1 to 2. Suitably, if r is 1 
then the thiol group is at the para-position; if  r is 2 then the 
thiol groups are at the meta-positions.
Thiols 39, 40, 50 and 51 (shown below) are exemplary 
capping agents for this reaction.
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10
Thiols 44, 45, 55 and 56 (shown below) are exemplary 
copolymerization agents for this reaction.
5
(IV)
10 wherein R2 is a halogen, such as Cl, Br or F or a secondary 
amine, such as
15
Rio
44 20 R4 is
The Sharpless “Click” Reaction
The Sharpless “click” reaction is a highly reliable reaction 
(FIG. 11) and can be performed under aqueous mild condi- 55 
tions. The reaction partners—the terminal alkyne and the 
alkylazide—are readily accessible stable functional groups. 
The mild reaction conditions are compatible with many func­
tional groups including those in oligonucleotides. One of 
ordinary skill in the art can readily determine suitable reac- 60 
tion conditions. For example, for a 1 mmol oligonucleotide 
synthesis, one can use about 10 mmol to about 100 mmol of 
each of the copolymerization agents, about 0.05 mmol to 
about 5.0 mmol CuS04 and about 0.05 mmol to about 5.0 
mmol sodium ascorbate. 65
Suitable capping agents for purification using the Sharp­
less “click” reaction include compounds of formula (IV)
wherein Rs is
(VI)
11
US 7,850,949 B2
12
n is independently an integer from 1 to 5, 
t is an integer from 1 to 3;
R9 is an electron withdrawing group such as cyano, COOR10, 
S 0 2Ph and N 0 2;
R10 is lower alkyl
Alkynes 57-60 (shown below) are exemplary capping 
agents for this reaction.
57
Grubbs’ ROMP Reaction
The ring opening metathesis polymerization (ROMP) 
15 reaction is also useful for oligonucleotide purification. The 
polymerization reaction can be performed in aqueous solu­
tion using water soluble catalysts (67-69, FIG. 14), and the 
reaction tolerates a wide range of functional groups. One of 
ordinary skill in the art can readily determine suitable poly­
merization conditions. Forexample, fora 1 mmol oligonucle­
otide synthesis, one can use about 10 mmol to about 100 
mmol of a copolymerization agent, about 0.02 mmol to about 
2.0 mmol cross-linking copolymerization agent that contains 
25 more than one alkene function such as 78 and 79, and about 
0.01 mmol to about 1.0 mmol metathesis catalyst.
The substrates for polymerization can be those such as 70 
and 71 as shown in FIG. 15. Suitable catalysts for the ROMP 
purification include, but are not limited to, catalyst 69. After 
30 polymerization, the catalyst may be removed by extraction 
with organic solvents such as CF12C12.
The capping agent is suitably a compound of formula 
58 (VII):
35
40
Ri
I
R6c r
(VII)
59
wherein Rj is halogen, such as Cl, Br or F or a secondary
R6is
Compounds 65 and 66 are exemplary copolymerization 
agents.
X is independently O or CF12;
R9 is an electron withdrawing group such as cyano, 
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and 
n is independently an integer from 1 to 5.
US 7,850,949 B2
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A suitable copolymerization agent is a compound of for­
mula (VII)
(VIII)
o
II
RgO— P —  ORg
OH
wherein R6 is
X is independently O or CH2; and 
n is independently an integer from 1 to 5. 
Compounds 74-77 are exemplary capping agents.
ization agent and about 0.2 mmol to about 2.0 mmol of a 
cross-linking thiol that contains more than 2 thiols in one 
molecule such as 56 and 86 in a suitable buffer such as 
phosphate buffered saline buffers and at a suitable tempera- 
5 ture such as room temperature and 60° C. Suitable capping 
reagents are compounds of formula (IX)
10
(IX)
wherein R2 is halogen, such as Cl, Br or F or a secondary 
amine, such as
74, X = O
75, X = CH2
76, X = O
77, X = CH2
Compounds 78, 79, 139, and 140 are exemplary copoly­
merization agents.
40
45
R9 is an electron withdrawing group such as cyano, 
COOR10, S 0 2Ph and N 0 2;
R10 is lower alkyl; and 
n is independently an integer from 1 to 5.
One of the R7 may also be any functionality that contains 2 
or more a,p-unsaturated carbonyl functions
Suitable copolymerization agents include compounds of 
formula (III):
wherein n is an integer from 1 to 5;
139, X
140, X
0 ,n  = 1-5 
CH2, n = 1-5
q is independently an integer from 0 to 3; and 
r is independently an integer from 1 to 2. Suitably, if r is 1 
then the thiol group is at the para-position; if  r is 2 then the 
thiol groups are at the meta-positions, 
or a compound of formula (X):
Conjugate Addition Reaction Between Maleimide and Thiol 
The conjugate addition reaction between maleimide and 
thiol (FIG. 25) is widely used in bioconjugate chemistry. This 
reaction can be performed in different aqueous buffers in a 60 
relatively wide range of pFl values (6.5-9) at room tempera­
ture, and the reaction is known to be compatible with oligo­
nucleotides. One of ordinary skill in the art can readily deter­
mine suitable reaction conditions. For example, for a 1 mmol 
oligonucleotide synthesis, one can use about 10 mmol to 65 
about 100 mmol of a bis-thiol copolymerization agent, about 
10 mmol to about 100 mmol of a bis-maleimide copolymer-
wherein n is an integer from 1 to 5 or a compound of 
formula (XI):
15
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(XI)
5
wherein q is an integer from 0 to 3; and 
t is independently an integer from 1 to 3. Suitably, if  t is 2 
then the thiol groups are para to each other; if t is 3 then the 
thiol groups are in the meta-positions.
Compounds 82 and 83 are exemplary capping agents.
Compounds 55, 56, 84, 85 and 86 are exemplary copoly­
merization agents.
40
55
-continued
84
85
86
Amide Formation Between an Ester and an Amine
Amines can react with carboxylic acid derivatives to form 
amides. This reaction can also be used as the polymerization 
reaction for purification of oligomers that are synthesized 
step-wise. One possible such polymerization reaction is 
shown here:
O O
65
wherein R12 is a suitable leaving group, such as CF13, 
CH2CH3, CH2CH2OCH3, CH2CH2OPh, or OPh;
Rn  is selected from hydrogen or lower alkyl3;
a is an integer from 1 to 6; and
b is an undetermined integer.
When using such polymerization reactions to purify oligo­
mers, a suitable condition for a 1 mmol oligomer synthesis, is: 
about 10 mmol to about 100 mmol of a copolymerization 
agent and about 0.2 mmol to about 2 mmol of a cross-linking 
copolymerization agent. The oligonucleotides do not need to 
be deprotected/cleaved prior to polymerization. The oligo­
nucleotides on solid support can be treated directly under 
these polymerization conditions. The oligonucleotides will 
be deprotected/cleaved by the amino group in the copolymer­
ization monomer. The advantages of this method include 
incorporation of both failure sequences and small molecules 
resulted from deprotection such as acetyl amide into the poly­
mer and no need for separate deprotection and cleavage step.
Suitable capping agents for purification using the amide 
bond formation reaction for polymerization includes com­
pounds of formula (XU):
17
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R 130  o r 13
wherein Rj is halogen, such as Cl, Br or F or a secondary 
amine such as
^Rio
----- N
\
Rio,
R13 may be
O
wherein R9 is an electron withdrawing group such as cyano, 
COOR10, S 02Ph and N 0 2;
R10 is lower alkyl;
R12 is a suitable leaving group, such as CF13, CF12CF[3, 
CH2CH2OCH3, CH2CH2OPh, or OPh; and
a is an integer from 1 to 6.
One of the R12 groups may also be any functionality that 
contains 2 or more ester groups.
Suitable copolymerization reagents include but are not 
limited to
wherein R12 is a suitable leaving group, such as CF13, 
CH2CH3, CH2CH2OCH3, CH2CH2OPh, or OPh;
Rn  is selected from the group consisting of hydrogen or 
lower alkyl;
Y = 0  or S; and
a is an integer from 1 to 6.
Suitable cross-linking copolymerization agents include but 
are not limited to:
NHRn NHRn
wherein R12 is a suitable leaving group, such as CF13, 
CH2CH3, CH2CH2OCH3, CH2CH2OPH, or OPh;
Rj j is selected from the group consisting of hydrogen and 
lower alkyl;
Compounds 141,142,143, and 144 are exemplary capping 
agents for this reaction:
18
Compounds 145,146,147,148 are exemplary copolymer­
ization agents for this reaction:
Compound 149 is an exemplary cross-linking copolymer­
ization agent for this reaction:
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Polymerization of Full Length Oligomer
In another embodiment of the present invention, the poly­
merization reactions can be used to polymerize the desired 
full-length oligomer sequence. In this embodiment, the cap­
ping agent is the normal acetic anhydride or any other suitable 5 
capping agent, but at the end of solid phase synthesis, a 
phosphoramidite that contains a suitable polymerizable func­
tional group is coupled to the end of the oligomer through a 
cleavable linker. Because failure sequences are all capped 
with acetic anhydride in each synthetic cycle, only the full
19
length sequence contains the polymerizable functional group. 
After synthesis, deprotection and cleavage, the crude oligo­
mer is subjected to polymerization; the full length sequence is 
incorporated into the polymerized material while failure 
sequences and other impurities remain in solution, which can 
be removed by filtration or extraction with a buffer. The pure 
full length sequences are then cleaved from the polymerized 
material and extracted with a buffer.
Suitable phosphoramidites include compounds 92, 95, 
103, 105, 113,115,122, 124, 132, 134, 150,151:
20
21
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-continued
o
132
Polymerization of Small Molecule Impurities
In yet another embodiment of the present invention, small 55 
molecule impurities can be incorporated into the polymerized 
material and removed along with the failure sequences. In this 
embodiment, the protecting groups contain a polymerizable 
functional group, and are also incorporated into the polymer- 
ized material. Here, the Sharpless “click” reaction is used as 
example.
The oligomer is synthesized under standard conditions. 
However the protecting groups for the nucleobases and the g5 
phosphate groups contain a polymerizable functional group. 
The following phosphoramidite monomers are exemplary:
23
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-continued
DMTiO
DMTrO
DMTiO
DMTr
If failure sequences are capped with agents such as 57-60, 
after cleavage/deprotection, the failure sequence and the 
small molecules resulted from the protecting groups will all 
be incorporated into the polymerized material. The full length 
sequence can be obtained by filtration and extraction. Alter­
natively, the failure sequences can be capped with a tradi-
tional capping agent, such as acetic anhydride and one of the 
phosphoramidites shown below can be used in the last syn­
thetic cycle.
24
o
5
10
15
20
25
30
35
40
45
50
55
60
65
25
US 7,850,949 B2
-continued
After synthesis and cleavage/deprotection, the full length 
sequence and the small molecule impurities resulting from 
protecting groups are incorporated into the polymerized 
material upon initiation of the polymerization reaction. The 
failure sequences can be removed by washing. The full length 
sequences (not small molecules resulted from protecting 
groups) are then cleaved from the polymer and extracted with 
buffer.
Kits for Purifying Oligomers
A further embodiment of the present invention is a kit 
comprising either a capping agent having a polymerizable 
functional group or a compound having a polymerizable 
functional group for attaching to the end of the full length 
oligomer. Kits can further comprise monomers, coupling 
reagents, polymerization reagents, buffers, cleavage agents, 
and other components necessary to synthesize and purify an 
oligomer in accordance with the present invention.
As used in this specification and the appended claims, the 
singular forms “a,” “an,” and “the” include plural referents 
unless the content clearly dictates otherwise. It should also be 
noted that the term “or” is generally employed in its sense 
including “and/or” unless the content clearly dictates other­
wise. All publications, patents and patent applications refer­
enced in this specification are indicative of the level of ordi­
nary skill in the art to which this invention pertains. All 
publications, patents and patent applications are herein 
expressly incorporated by reference to the same extent as if 
each individual publication or patent application was specifi­
cally and individually indicated by reference. In case of con­
flict between the present disclosure and the incorporated pat­
ents, publications and references, the present disclosure 
should control.
It also is specifically understood that any numerical range 
recited herein includes all values from the lower value to the 
upper value, i.e., all possible combinations of numerical val­
ues between the lowest value and the highest value enumer­
ated are to be considered to be expressly stated in this appli­
cation. For example, if  a concentration range is stated as 1% 
to 50%, it is intended that values such as 2% to 40%, 10% to 
30%, or 1% to 3%, etc., are expressly enumerated in this 
specification.
The following examples are provided to assist in a further 
understanding of the invention. The particular materials, 
methods and conditions employed are intended to be illustra­
tive of the invention and are not limiting upon the scope of the 
invention.
EXAMPLES 
Example 1
Purification Via Radical Acrylamide Polymerization 
of Failure Sequences
After synthesis, the oligonucleotide 25 is cleaved and 
deprotected under standard basic conditions (for example, 
K2C 0 3, anhydrous methanol, room temperature, 24 hours 
and concentrated ammonium hydroxide, 60° C.). The crude
oligonucleotides are subjected to polymerization conditions, 
e.g. (NFl4)2S20 8/TMEDA/water/r.t./l h, to incorporate the 
failure sequences into polymer. The full length sequence 25 
(FIG. 5) remains in solution or in the polymer matrix because 
it does not contain an acrylamide function. Collection of the 
full length sequence can be achieved by filtration and/or 
extraction from the polymer gel using a buffer. Impurities 
resulting from the protecting groups in the synthesis such as 
acrylonitrile benzamide, acetamide and isobutyramide can be 
removed by first dissolving the material in sodium acetate 
buffer and then precipitating the oligonucleotide with 2-pro- 
panol (for less than 15 -mer) or ethanol (for more than 15 -mer) 
at -10° C. The small organic impurities remain in solution. 
Alternatively, protecting groups containing acrylamide func­
tions can be used so that all small organic impurities can be 
removed by polymerization.
Example 2
Synthesis of Thiol Capping Agents and Purification 
Using Disulfide Formation of Failure Sequences
As shown in FIG. 7, 34 is converted to 36 using 35, and 
acetylated to give 37. Then 37 is converted to 39 or 40 using 
similar procedures for preparing 22-24. Alternatively, 37 can 
be synthesized from 41 in one pot as shown in FIG. 7. The 
thiols 44 and 45, which are required for copolymerization, 
can also be readily synthesized (FIG. 8).
After synthesis and deprotection/cleavage, the crude oli­
gonucleotide is subjected to polymerization conditions in the 
presence of 44 and 45 mentioned above. Full length oligo­
nucleotides are collected by filtration and/or extraction. Small 
organic impurities can be removed by precipitation.
Alternatively, thiols 50 and 51 can be used for capping 
failure sequences, and 55 and 56 can be used as copolymer­
ization agents. Their syntheses are illustrated in FIGS. 9 and 
10. Compound 48 is prepared from 46 and NBS followed by 
reacting with AcS- under basic conditions (FIG. 9), which is 
then converted to the capping agents 50 and 51 using the 
above described conditions. The copolymerization agents 55 
and 56 are readily available as shown in FIG. 10 from com­
pounds 52 and 48. The oligonucleotide synthesis, capping 
failure sequences with 39, 40, 50 or 51, deprotection/cleav­
age, polymerization in the presence with 44 and 45 or 55 and 
56, purification and analysis of purification results are the 
same as previously described.
Example 3
Synthesis of Capping Agents and Purification via 
Sharpless “Click” Polymerization of Failure
Sequences
The capping agents that contain terminal alkynes (57-60) 
can be easily synthesized according to FIG. 12 from 61 and 
62. The polymerization partner 65 is prepared by reacting 63 
with 3-bromo-1 -propanol to give 64, followed by treating 
with sodium azide (FIG. 13). The other copolymerization 
partner 66 is prepared similarly from propargyl alcohol 61 
and 63 (FIG. 13). The oligonucleotide synthesis, capping 
failure sequences with 57-60, deprotection/cleavage, poly­
26
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merization in the presence of 65 and 66, purification and 
analysis of purification results are the same as above.
Example 4
Synthesis of Capping Agents for Purification Via 
Grubb’s Ring Opening Metathasis Polymerization of 
Failure Sequences
The synthesis of the capping agents 74-77 is shown in FIG. 
16. Compounds 72 and 73 can be synthesized from 70 (this 
compound can be prepared readily by stirring the solution of 
maleic anhydride and furan in ether at room temperature for 
12 hours; the exo isomer is formed exclusively as a white 
precipitate) and 71 (both are commercially available and can 
be prepared using known procedures) by heating with 
3-amino-l -propanol under vacuum in high yields. These two 
compounds are then converted to the capping agents 74-77 
under conditions described above. Suitably, the exo isomers 
of these compounds are used. The water soluble copolymer­
ization monomers 78 and 79 can be synthesized similarly 
(FIG. 16). The oligonucleotide synthesis, capping failure 
sequences with 74-77, deprotection/cleavage, polymeriza­
tion in the presence of 78 or 79, purification and analysis of 
purification results are the same as described.
Example 5
Synthesis of Capping Agents and Purification Via 
Conjugate Addition of Maleimide and Thiol of 
Failure Sequences
The synthesis of the capping agents 82 and 83 is shown in 
FIG. 18. Commercially available maleic anhydride (80) is 
condensed with 1 -amino-3 -propanol to give 81, which will be 
converted to the capping agents 82 and 83 under conditions 
described earlier. The copolymerization agents 55 and 56 are 
described earlier; 84-86 can be synthesized easily by one of 
ordinary skill in the art. After synthesizing oligonucleotide on 
solid support using standard phosphoramidite chemistry and 
capping failure sequences with 82 (with activator such as 
lFl-tetrazole) or 83 (with base such as Et3N), the crude oli­
gonucleotide will be mixed with 55, 56 and 84 to incorporate 
the failure sequences into polymer using reported conjugate 
addition conditions. Alternatively, 84-86 may be used for 
copolymerization.
Example 6
Synthesis of Capping Agents and Purification Via
Amide Bond Formation Reaction to Incorporate 
Failure Sequences Into Polymer
The synthesis of the capping agent 141 is shown in FIG. 34. 
After synthesizing oligonucleotide on solid support using 
standard phosphoramidite chemistry and capping failure 
sequences with 141 the crude oligonucleotide is not cleaved 
or deprotected. The solid support is then directly treated with 
copolymerization agent 145 at 60° C. for 12 hours. Then 
cross-linking copolymerization agent 149 is added and the 
mixture is thenheatedto about 90° C. for 6 hours. The failure 
sequences and small molecules that resulted from deprotec­
tion are now incorporated into polymer, while the full length
27
sequence remains in solution or in polymer matrix. Filtration 
and extraction provide pure full-length sequence.
Example 7
Synthesis of Phosphoramidites 92 and 95 and 
Purification Via Radical Acrylamide Polymerization 
of Full-Length Oligomers
As shown in FIG. 19, the reaction between acetonitrile and 
acetone produces 87, which is reduced to the amine 88. Com­
pound 88 reacts with acryloyl chloride to produce 89 in the 
presence of a base. The tertiary hydroxyl group in 89 is 
silyatedwith 1 equivalent dichlorodiisopropylsilane followed 
by addition of thymidine (suitably protected other nucleo- 
bases can also be used, but are not described in this proposal), 
and this affords 90. The tertiary hydroxyl groups in 89 have 
two advantages: they stabilize the diisopropylsilyl acetal link­
age in 90, and they prevent dimer formation when 89 is mixed 
with dichlorodiisopropylsilane. Compound 90 is phosphiny- 
lated with 91 to produce the target phosphoramidite 92 under 
standard conditions. 5'-OFl oligonucleotide can be produced 
using 92 for purification. 5'-phosphate oligonucleotides can 
be purified using the phosphoramidite 95. Phosphoramidite 
95 can be synthesized by reacting 89 with 1 equivalent dichlo­
rodiisopropylsilane followed by addition of the commercially 
available 93 to afford 94, which is phosphinylated to produce 
95 under standard conditions (FIG. 19).
Oligonucleotides can be synthesized using a solid phase 
synthesizer under standard conditions using phosphoramidite 
methodology. At the end of synthesis, phosphoramidite 92 or 
95 is coupled to the 5'-end of oligonucleotide on the synthe­
sizer.
After deprotection and cleavage, oligonucleotide 96 (when 
92 is used) or 97 (when 95 is used) is produced, along with 
failure sequences and small organic impurities. The failure 
sequences and impurities do not contain the acrylamide func­
tionality. The crude oligonucleotide is then subjected to poly­
merization conditions, such as acrylamide, N,N'-methyl- 
enebisacrylamide, (NFl4)2S20 8, TMEDA, r.t., 1 h. The full 
length sequence 96 or 97 is incorporated into a polymer, and 
the failure sequences and small organic impurities remain in 
solution.
The failure sequences and small organic impurities can be 
removed by filtration or extraction. The gel that contains the 
full length sequence is washed with water, DMF and TF1F. 
This is followed by treatment with fluoride ion (TBAF or 
FIF/pyridine, r.t. FIG. 21) resulting in oligonucleotide 98 or 
99. Oligonucleotide 98 is the target full length sequence with 
5'-OH group. Oligonucleotide 99 can be treated with concen­
trated methylamine to give oligonucleotide 100.
Example 8
Synthesis of Phosphoramidites 103 and 105 and 
Purification Via Disulfide Formation of Full-Length
Oligomers
Phosphoramidites 103 and 105 are synthesized according 
to FIG. 22. The amino alcohol 88 is reacted with carboxylic 
acid 37 (48 can also be used to give 101, which is coupled with 
thymidine through the diisopropylsilyl acetal linker, and 
phosphinylated to give phosphoramidite 103. For 5'-phos- 
phate oligonucleotide synthesis, 101 is coupled with 93 using 
the diisopropylsilyl acetal linker, and phosphinylated to 
afford phosphoramidite 105. Using 103 or 105 as phosphora­
midite in the last synthetic cycle in oligonucleotide synthesis,
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after deprotection/cleavage, the oligonucleotide has a struc­
ture as shown by 106 or 107. Polymerization in the presence 
of 44 and 45 incorporates 106 or 107 into polymer (see 108 
and 109, FIG. 24). After removing failure sequences and 
other impurities by filtration or extraction, oligonucleotides 
98 or 100 are collected as described above (FIG. 24).
Example 9
Synthesis of Phosphoramidites 113 and 115 and 
Purification Via Sharpless “Click” Polymerization of 
Full-Length Oligomers
Phosphoramidites 113 and 115 are synthesized according 
to FIG. 25. The known alkyne 110 (can be synthesized from 
inexpensive materials) is hydrolyzed, and coupled with 88 to 
give 111, which is converted to the thymidine analog 112 and 
phosphinylated to afford the phosphoramidite 113. The phos- 
phoramidite 115 is synthesized from 111 and 93 in the same 
way as described for the synthesis of 105. Using 113 or 115 as 
phosphoramidite in the last synthetic cycle in oligonucleotide 
synthesis, after deprotection and cleavage, the oligonucle­
otide has a structure as shown by 116 or 117. Polymerization 
in the presence of 65 and 66 incorporates 113 or 115 into 
polymer (see 118 and 119, FIG. 27). After removing failure 
sequences and other impurities by washing, oligonucleotides 
98 or 100 is collected as described above.
Example 10
Synthesis of Phosphoramidites 122 and 124 and 
Purification Using Via Grubb’s Ring Opening 
Metathasis Polymerization of Full-Length Oligomers
The required phosphoramidites 122 and 124 are synthe­
sized according to FIG. 28. Compound 70 is reacted with 88 
to give 120, which is converted to the thymidine analog 121 
and phosphinylated to afford the phosphoramidite 122. The 
phosphoramidite 124 is synthesized from 120 and 93 in the 
same way as described for the synthesis of 105. Using 122 or 
124 as phosphoramidite in the last synthetic cycle in oligo­
nucleotide synthesis, after deprotection and cleavage, the oli­
gonucleotide has a structure as shown by 125 or 126. Poly­
merization in the presence of 78 incorporates 125 or 126 into 
polymer (see 127 and 128, FIG. 30). After removing failure 
sequences and other impurities, oligonucleotides 98 or 100 
are collected as described above.
Example 11
Synthesis of Phosphoramidites 132 and 134 and 
Purification Via Conjugate Addition of Maleimide 
and Thiol Full-Length Oligomers
The required phosphoramidites 132 and 134 are synthe­
sized according to FIG. 31. Compound 129 (which can be 
prepared from 3,5-diaminobenzoic acid and maleic anhy­
dride) is reacted with 88 to give 130, which is converted to the 
thymidine analog 131 and phosphinylated to afford the phos­
phoramidite 132. The phosphoramidite 134 is synthesized 
from 130 and 93 in the same way as described for the synthe­
sis of 105. Using 132 or 134 as phosphoramidite in the last 
synthetic cycle in oligonucleotide synthesis, after deprotec­
tion and cleavage, the oligonucleotide has a structure as 
shown by 135 or 136 (FIG. 32). Polymerization in the pres­
ence of 84, 85 and 86 incorporates 135 or 136 into polymer 
(see 137 and 138, FIG. 33). After removing failure sequences 
and other impurities, oligonucleotides 98 or 100 are collected 
as described above.
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Example 12
Synthesis of Phosphoramidites and Purification Via 
Incorporation of Full Length Sequence into Polymer 
using the Amide Bond Formation Reaction
Phosphoramidite 150 is synthesized according to FIG. 35. 
Using phosphoramidite 150 in the last synthetic cycle, the 
oligonucleotide synthesized on the solid support has structure 
152:
152
Structure 152 is then treated with 146 at about 60° C. for 
about 6 hours, without standard basic deprotection or cleav­
age. During the reaction, the phenoxide in the full length 
sequence is displaced by the amino group in 146. Next, the 
cross-linking copolymerization reagent 149 is added and the 
mixture heated to 90° C. for about 6 hours. During this reac­
tion the oligonucleotides are cleaved from the solid support, 
all protecting groups are removed, and the full length 
sequence and the small molecules resulting from the protect­
ing groups are incorporated into a polymerized material. Pure 
full length sequence will be collected by treating with fluoride 
as described above.
All patents, publications and references cited herein are 
hereby fully incorporated by reference. In case of conflict 
between the present disclosure and incorporated patents, pub­
lications and references, the present disclosure should con­
trol.
The invention claimed is:
1. A method of purifying an oligomer comprising:
capping any failure sequences produced during synthesis 
with a capping agent haying a polymerizable functional 
group;
polymerizing the capped failure sequences; and
separating the polymerized material from the full-length 
oligomer;
wherein the capping agent is a compound of formula (IV):
/ r \
R4O OR4
wherein Rx is a halogen or a secondary amine; 
R4 is
(CH2)t
t is an integer from 1 to 3.
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